Assessing Non-adjunctive CGM Safety at Home and in New Markets

NCT ID: NCT04585139

Last Updated: 2022-08-01

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 85 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-10-06
• Study Completion Date: 2022-02-07

Brief Summary

The purpose of the study is to examine whether non-adjunctive (without having to double check using another method) use of Continuous Glucose Monitoring improves A1c in adults or children with diabetes managed by intensive insulin therapy.

Conditions

Diabetes Mellitus

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: SUPPORTIVE_CARE
• Blinding Strategy: NONE

Study Groups

Phase 1 -- Introduction to Dexcom G6 CGM

A 2 week run-in wear period of blinded CGM followed by 12 weeks of wear of a Commercially available CGM

Group Type: OTHER

Phase 1- Introduction to Dexcom G6 CGM

Intervention Type: DEVICE

Examine whether non-adjunctive use of CGM improves glycemic control in adults with diabetes managed by intensive insulin therapy

Phase 2 -- Comparison of an Updated G6 Transmitter to Commercial Dexcom G6 CGM

1 group will wear a Commercially available CGM for 12 weeks while the 2 group will wear an Updated CGM for 12 weeks.

Group Type: ACTIVE_COMPARATOR

Phase 1- Introduction to Dexcom G6 CGM

Intervention Type: DEVICE

Examine whether non-adjunctive use of CGM improves glycemic control in adults with diabetes managed by intensive insulin therapy

Interventions

Phase 1- Introduction to Dexcom G6 CGM

Examine whether non-adjunctive use of CGM improves glycemic control in adults with diabetes managed by intensive insulin therapy

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Age 2 years or older
• A diagnosis of T1D or T2D made at least 6 months prior to enrollment. At least 20 adult participants will have T1D; and 10 will have T2D; 10 participants will be over age 65 years.
• Using IIT (either an insulin pump or MDI)
• HbA1c value ≥ 7.5% (≥ 58 mmol/mol) measured by local lab within prior 30-days before enrollment or by point of care at time of screening.
• eGFR ≥ 30 within the last 90-days prior to enrollment (adult participants only)
• Currently performing 2 or more SMBG fingersticks a day by historical average and willing to continue this during the blinded CGM wear.

Exclusion Criteria

• Use of real-time or intermittently scanned CGM in the 6 months prior to enrollment.
• BMI > 45.
• Anticipated changes to insulin delivery method or insulin formulation(s).
• Insulin formulation changes within class will be permitted if required per formulary change and represent equivalent therapy (eg: insulin lispro change to insulin aspart).
• Pregnancy (as demonstrated by a positive test at study entry) at time of screening or are planning to become pregnant during the study.
• Applicable only to women of reproductive potential.
• Planned or currently using weight reduction medications, programs or surgery. Defined as 1) using weight loss medications and losing weight (e.g. chronic use of weight loss medications with stable weight is not exclusionary) or planning on using weight loss prescription medication during the study; 2) currently using or planning on initiating a modified fasting program (e.g. protein-sparing diet plans) during the study; or 3) bariatric surgical procedure within the past year or plans for undergoing bariatric surgery during the study.
• Concomitant disease or condition that may compromise patient safety including, but not limited to; severe mental illness, a diagnosed or suspected eating disorder or any uncontrolled long-term medical/psychiatric condition that would interfere with study- related tasks or visits, including ongoing treatment for a significant malignancy. These assessments/conditions are made at investigator's discretion.
• Known (or suspected) significant allergy to medical-grade adhesives.
• Any condition, per investigator assessment, that could impact the stability of the HbA1c measurement, for example,
• Acute or chronic blood loss or bleeding disorder,
• Red blood cell transfusion or erythropoietin, administration in the 3 months prior to enrollment,
• Or red blood cell transfusion or erythropoietin administration anticipated during the course of the study.
• Anticipated acute use of oral or injectable glucocorticoids that could affect glycemic control and impact HbA1c, for example,
• Frequent steroid bursts used for inflammatory arthritis or inflammatory bowel disease,
• Or recurrent lumbar epidural steroid injections,
• Current treatment with hydroxyurea
• Participation in another pharmaceutical or device trial at the time of enrollment or during the study.

• Minimum Eligible Age: 2 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Jaeb Center for Health Research

OTHER

Sponsor Role: collaborator

DexCom, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Las Vegas Endocrinology

Henderson, Nevada, United States

Countries

United States

Other Identifiers

PTL-903833

Identifier Type: -

Identifier Source: org_study_id